Cargando…
Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Croatian Society of Medical Biochemistry and Laboratory Medicine
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564152/ https://www.ncbi.nlm.nih.gov/pubmed/37841774 http://dx.doi.org/10.11613/BM.2023.031201 |
| _version_ | 1785118444540133376 |
|---|---|
| author | Gomerčić Palčić, Marija Matijaca, Hana Kruljac, Ivan Vusić, Lucija Hostić, Vedran Vrbanić, Luka Mrsić, Fanika Zrilić, Radovan Ćelap, Ivana Gaćina, Petar |
| author_facet | Gomerčić Palčić, Marija Matijaca, Hana Kruljac, Ivan Vusić, Lucija Hostić, Vedran Vrbanić, Luka Mrsić, Fanika Zrilić, Radovan Ćelap, Ivana Gaćina, Petar |
| author_sort | Gomerčić Palčić, Marija |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10564152 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Croatian Society of Medical Biochemistry and Laboratory Medicine |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105641522023-10-15 Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience Gomerčić Palčić, Marija Matijaca, Hana Kruljac, Ivan Vusić, Lucija Hostić, Vedran Vrbanić, Luka Mrsić, Fanika Zrilić, Radovan Ćelap, Ivana Gaćina, Petar Biochem Med (Zagreb) Corrigendum Croatian Society of Medical Biochemistry and Laboratory Medicine 2023-10-15 2023-10-15 /pmc/articles/PMC10564152/ /pubmed/37841774 http://dx.doi.org/10.11613/BM.2023.031201 Text en Croatian Society of Medical Biochemistry and Laboratory Medicine. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Corrigendum Gomerčić Palčić, Marija Matijaca, Hana Kruljac, Ivan Vusić, Lucija Hostić, Vedran Vrbanić, Luka Mrsić, Fanika Zrilić, Radovan Ćelap, Ivana Gaćina, Petar Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience |
| title | Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience |
| title_full | Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience |
| title_fullStr | Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience |
| title_full_unstemmed | Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience |
| title_short | Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience |
| title_sort | corrigendum to: post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe covid-19 pneumonia - a single center experience |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564152/ https://www.ncbi.nlm.nih.gov/pubmed/37841774 http://dx.doi.org/10.11613/BM.2023.031201 |
| work_keys_str_mv | AT gomercicpalcicmarija corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience AT matijacahana corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience AT kruljacivan corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience AT vusiclucija corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience AT hosticvedran corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience AT vrbanicluka corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience AT mrsicfanika corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience AT zrilicradovan corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience AT celapivana corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience AT gacinapetar corrigendumtoposttreatmentneutrophiltolymphocyteratioasaprognostictoolinpatientstreatedwithtocilizumabforseverecovid19pneumoniaasinglecenterexperience |